Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is striking out in its attempts to broaden its label.